Edition:
United Kingdom

People: Adverum Biotechnologies Inc (ADVM.OQ)

ADVM.OQ on NASDAQ Stock Exchange Global Market

13.77USD
18 Jul 2019
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$13.77
Open
$15.23
Day's High
$15.23
Day's Low
$12.51
Volume
771,105
Avg. Vol
203,720
52-wk High
$16.38
52-wk Low
$2.62

Finer, Mitchell 

Mr. Mitchell H. Finer, Ph.D., is Director of the Company.Dr. Finer has served as a managing director of MPM Capital, a venture capital firm, since September 2015. Dr. Finer is a founder of Adverum, and previously served as one of our distinguished research fellows. Since April 2015, Mr. Finer has served as Chief Executive Officer and Chief Scientific Officer of Oncorus, Inc., a biotechnology company. Since April 2017, Mr. Finer has also served as interim Chief Executive Officer of CODA Biotherapeutics, Inc., a biopharmaceutical company. Previously, he served as Chief Scientific Officer of bluebird bio, Inc. (“bluebird”), a biopharmaceutical company, from March 2010 through July 2015. Prior to joining bluebird, Dr. Finer served as senior vice president of development and operations for Novocell, Inc. (now part of ViaCyte, Inc.), a stem cell engineering company, from November 2008 through March 2010. From July 2005 through November 2008, Dr. Finer served as Chief Executive Officer of Intracel Holdings LLC. He was also a founder and Vice President of Research for Cell Genesys Inc., and a founder of Abgenix, Inc. Dr. Finer received a B.A. in biochemistry and bacteriology from the University of California, Berkeley and a Ph.D. in biochemistry and molecular biology from Harvard University. He completed a postdoctoral fellowship at the Whitehead Institute for Biomedical Research. Dr. Finer has been chosen to serve on our Board due to his operational, strategic and corporate leadership experience and his experience as a founder of numerous biopharmaceutical companies

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --